@Ckatinos @sunrgu These combo trials are the future. $MRK and $AZN are way ahead. $BMY has lot of catching up to do. And $CLVS is one important piece of it. Besides that Lucitanib data (summer), if good, $CLVS can name the price that they would like to get bought. Until then, slow grind upwards.